RxSight Balance Sheet Health
Financial Health criteria checks 5/6
RxSight has a total shareholder equity of $277.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $310.5M and $33.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$237.12m |
| Equity | US$277.26m |
| Total liabilities | US$33.21m |
| Total assets | US$310.47m |
Recent financial health updates
We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04
RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Recent updates
RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24RxSight, Inc. (NASDAQ:RXST) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 11RxSight Non-GAAP EPS of -$0.50 beats by $0.15, revenue of $11.4M beats by $0.85M
Aug 08RxSight says FDA requires additional info for approval of light delivery device
Jul 12Financial Position Analysis
Short Term Liabilities: RXST's short term assets ($286.8M) exceed its short term liabilities ($22.6M).
Long Term Liabilities: RXST's short term assets ($286.8M) exceed its long term liabilities ($10.6M).
Debt to Equity History and Analysis
Debt Level: RXST is debt free.
Reducing Debt: RXST had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RXST has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RXST has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.